Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects

Journal of Clinical Pharmacology

Volumn 51, Issue 3, 2011, Pages 368-377

  Zhu, Li ^a   Persson, Anna ^a   Mahnke, Lisa ^a   Eley, Timothy ^a   Li, Tong ^a   Xu, Xiaohui ^a   Agarwala, Sangeeta ^a   Dragone, Jeffrey ^a   Bertz, Richard ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Atazanavir; drug drug interactions; HIV; omeprazole; pharmacokinetics

Indexed keywords

ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; OMEPRAZOLE;

ACNE; ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG PROTEIN BINDING; DRUG SAFETY; EVENING DOSAGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MORNING DOSAGE; NORMAL HUMAN; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AREA UNDER CURVE; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; OLIGOPEPTIDES; OMEPRAZOLE; PROTON PUMP INHIBITORS; PYRIDINES; RITONAVIR;

EID: 79951901370     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010367651     Document Type: Article

References (54)

1. Reyataz (atazanavir sulfate) [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2008.
2. Barreiro P, Rendon A, Rodriguez-Novoa S, Soriano V. Atazanavir: the advent of a new generation of more convenient protease inhibitors. HIV Clin Trials. 2005;6:50-61. (Pubitemid 40533114)
3. Busti AJ, Hall RG, Margolis DM. Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004;24:1732-1747. (Pubitemid 39578961)
4. Fuster D, Clotet B. Review of atazanavir: a novel HIV protease inhibitor. Expert Opin Pharmacother. 2005;6:1565-1572. (Pubitemid 41131695)
5. Perez-Elias MJ. Atazanavir: simplicity and convenience in different scenarios. Expert Opin Pharmacother. 2007;8:689-700. (Pubitemid 46547021)
6. Swainston HT, Scott LJ. Atazanavir: a review of its use in the management of HIV infection. Drugs. 2005;65:2309-2336. (Pubitemid 41573606)
7. Le Tiec C, Barrail A, Goujard C, Taburet AM. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet. 2005;44:1035-1050. (Pubitemid 41356390)
8. Cahn PE, Gatell JM, Squires K, et al. Atazanavir-a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials. J Int Assoc Physicians AIDS Care (Chic Ill). 2004;3:92-98.
9. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005;19:685-694. (Pubitemid 40593073)
10. Murphy RL, Sanne I, Cahn P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS. 2003;17:2603-2614. (Pubitemid 38402338)
11. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372:646-655.
12. Welage LS, Carver PL, Revankar S, Pierson C, Kauffman CA. Alterations in gastric acidity in patients infected with human immunodeficiency virus. Clin Infect Dis. 1995;21:1431-1438. (Pubitemid 26066634)
13. Luber A, Garg V, Gharakhanian S, Team VHP. Survey of medication used by HIV-infected patients that affect gastrointestinal acidity and potential for negative drug interactions with HAART. Abstract presented at: 7th International Congress on Drug Therapy in HIV Infection; November 2004; Glasgow, UK. Abstract P294.
14. Burgos A, Garrido J. Use of acid reducing agents among HIV infected patients receiving antiretrovirals in Spain. Paper presented at: 10th European AIDS Conference; November 17-20, 2005; Dublin, Ireland.
15. van Lunzen J, Liess H, Arastéh K, Walli R, Daut B, Schürmann D. Concomitant use of gastric acid-reducing agents is frequent among HIV-1-infected patients receiving protease inhibitor-based highly active antiretroviral therapy. HIV Med. 2007;8:220-225. (Pubitemid 46691692)
16. Agarwala S, Gray K, Wang Y, Grasela D. Pharmacokinetic effect of omeprazole on atazanavir co-administered with ritonavir in healthy subjects. Abstract presented at: 12th Conference on Retroviruses and Opportunistic Infections; February 2005; Boston, MA. Abstract 658.
17. Klein CE, Chiu YL, Cai Y, et al. Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir. J Clin Pharmacol. 2008;48:553-562. (Pubitemid 351503512)
18. Luber AD, Brower R, Kim D, Silverman R, Peloquin CA, Frank I. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers. HIV Med. 2007;8:457-464. (Pubitemid 47335268)
19. Tappouni HL, Rublein JC, Donovan BJ, et al. Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir. Am J Health Syst Pharm. 2008;65:422-428. (Pubitemid 351358344)
20. Sekar VJ, Lefebvre E, De Paepe E, et al. Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers. Antimicrob Agents Chemother. 2007;51:958-961. (Pubitemid 46355280)
21. Eley T, Agarwala S, Wang R, et al. Analysis of intra-gastric pH and atazanavir bioavailability in healthy subjects. Abstract presented at: 7th Workshop on Clinical Pharmacology in HIV Therapy; April 2006; Lisbon, Portugal. Abstract 40.
22. Lin JH, Chen IW, Vastag KJ, et al. pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs. Drug Metab Dispos. 1995;23:730-735.
23. McNicholl IR. Drug interactions among the antiretrovirals. Curr Infect Dis Rep. 2004;6:159-162. (Pubitemid 38906839)
24. Fulco PP, Vora UB, Bearman GM. Acid suppressive therapy and the effects on protease inhibitors. Ann Pharmacother. 2006;40:1974-1983. (Pubitemid 44747467)
25. Luber AD. Use of acid-reducing agents in protease inhibitor-based HAART and the potential for negative treatment outcomes. AIDS Read. 2005;15:692-700.
26. Kiser JJ, Lichtenstein KA, Anderson PL, Fletcher CV. Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection. Pharmacotherapy. 2006;26:511-514.
27. Tomilo DL, Smith PF, Ogundele AB, et al. Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. Pharmacotherapy. 2006;26:341-346. (Pubitemid 43334673)
28. Khanlou H, Farthing C. Co-administration of atazanavir with proton-pump inhibitors and H2 blockers. J Acquir Immune Defic Syndr. 2005;39:503. (Pubitemid 41003800)
29. Guiard-Schmid JB, Poirier JM, Bonnard P, et al. Proton pump inhibitors do not reduce atazanavir concentrations in HIV-infected patients treated with ritonavir-boosted atazanavir. AIDS. 2005;19:1937-1938. (Pubitemid 41546626)
30. Winston A, Bloch M, Carr A. The clinical correlations of trough plasma atazanavir levels in a cohort of HIV-1-positive individuals receiving HAART. Abstract presented at: 12th Conference on Retroviruses and Opportunistic Infections; February 2005; Boston, MA. Abstract 656.
31. Chan-Tack KM, Edozien A. Ritonavir-boosted atazanavir may be efficacious in HIV-infected patients concurrently receiving omeprazole. Clin Infect Dis. 2006;42:1344.
32. Furtek KJ, Crum NF, Olson PE, Wallace MR. Proton pump inhibitor therapy in atazanavir-treated patients: contraindicated? J Acquir Immune Defic Syndr. 2006;41:394-396.
33. Antoniou T, Yoong D, Beique L, et al. Impact of acid-suppressive therapy on virologic response to atazanavir-based regimens in antiretroviral-experienced patients: a case series. J Acquir Immune Defic Syndr. 2005;39:126-128. (Pubitemid 40617029)
34. Sahloff EG, Duggan JM. Clinical outcomes associated with concomitant use of atazanavir and proton pump inhibitors. Ann Pharmacother. 2006;40:1731-1736. (Pubitemid 44544868)
35. Katz PO, Frissora C. The pharmacology and clinical relevance of proton pump inhibitors. Curr Gastroenterol Rep. 2002;4:459-462.
36. Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs. 2003;63:2739-2754. (Pubitemid 38049991)
37. Katz PO, Xue S, Castell DO. Control of intragastric pH with omeprazole 20 mg, omeprazole 40 mg and lansoprazole 30 mg. Aliment Pharmacol Ther. 2001;15:647-652. (Pubitemid 32385869)
38. Rohss K, Hasselgren G, Hedenstrom H. Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci. 2002;47:954-958. (Pubitemid 34439168)
39. Rohss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol. 2004;60:531-539. (Pubitemid 39517904)
40. Tolman KG, Sanders SW, Buchi KN, Karol MD, Jennings DE, Ringham GL. The effects of oral doses of lansoprazole and omeprazole on gastric pH. J Clin Gastroenterol. 1997;24:65-70. (Pubitemid 27142924)
41. Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole - a gastric proton pump inhibitor-on pentagastrin stimulated acid secretion in man. Gut. 1983;24:270-276. (Pubitemid 13159786)
42. Sachs G, Shin JM, Briving C, Wallmark B, Hersey S. The pharmacology of the gastric acid pump: the H+,K+ ATPase. Annu Rev Pharmacol Toxicol. 1995;35:277-305.
43. Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol. 2004;95: 2-8. (Pubitemid 38993131)
44. Laine L. Acid secretion in human immunodeficiency virus infection. Gastroenterology. 1993;105:298-299.
45. Lake-Bakaar G, Elsakr M, Hagag N, et al. Changes in parietal cell structure and function in HIV disease. Dig Dis Sci. 1996;41:1398-1408. (Pubitemid 26245921)
46. Goicoechea M, Best B, Capparelli E, Caperna J, Ballard C, Haubrich R. Therapeutic ritonavir-boosted atazanavir plasma concentration and concurrent omeprazole use. AIDS. 2006;20:2127-2128. (Pubitemid 44611070)
47. Malan DR, Krantz E, David N, et al. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr. 2008;47:161-167. (Pubitemid 351172182)
48. Cleijsen RM, van de Ende ME, Kroon FP, et al. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. J Antimicrob Chemother. 2007;60:897-900. (Pubitemid 47434275)
49. Zhu L, Liao S, Absalon J, et al. Exploration of pharmacokinetic/ pharmacodynamic relationships of boosted atazanavir and lopinavir over 48 weeks in HIV-infected treatment naive patients: CASTLE study. Abstract presented at: 10th International Workshop on Clinical Pharmacology of HIV Therapy, April 2009; Amsterdam, The Netherlands. Abstract 19.
50. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents - a working group of the Office of AIDS Research Advisory Council (OARAC). http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Retrieved December 1, 2009.
51. Robinson BS, Riccardi KA, Gong YF, et al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother. 2000;44:2093-2099. (Pubitemid 30484432)
52. Calvet X, Gomollon F. What is potent acid inhibition, and how can it be achieved? Drugs. 2005;65(suppl 1):13-23.
53. Lind T, Rydberg L, Kyleback A, et al. Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2000;14:861-867. (Pubitemid 30446896)
54. Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther. 1998;12:1235-1240. (Pubitemid 28565964)